These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7655371)

  • 1. Allorecognition and graft-versus-host disease.
    Theobald M
    Bone Marrow Transplant; 1995 Apr; 15(4):489-98. PubMed ID: 7655371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of recipient-specific alloreactivity: is GVHD predictable?
    Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H
    Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of alloreactive cytotoxic and lymphokine-secreting T lymphocytes in the development of acute graft-versus-host disease.
    Theobald M
    Transfus Sci; 1994 Sep; 15(3):189-96. PubMed ID: 10155540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.